Advertisement

Invention and Early History of Morpholinos: From Pipe Dream to Practical Products

  • James E. Summerton
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1565)

Abstract

Beginning with my concept in 1969 to treat disease at the nucleic acid level using antisense nucleic acids, antisense has evolved to the current Morpholino oligos. Morpholinos have been the dominant gene knockdown system in developmental biology. Lack of delivery technologies has limited their use in adult animals (including humans), though alteration in muscles in Duchenne muscular dystrophy (DMD) allows delivery into adult muscle. Morpholinos are currently in Phase 3 clinical trials for DMD and a Morpholino oligo for skipping dystrophin exon 51 has been approved by the US FDA. With improved delivery techniques, such as those in development at Gene Tools, therapeutic Morpholinos for many difficult-to-treat diseases will be possible. Initial applications are expected to be custom cocktails of delivery-enabled Morpholinos for treating cancers.

Key words

Morpholino oligomers Antisense Anti-gene History Delivery 

References

  1. 1.
    Ekker S (2000) Morphants: a new systematic vertebrate functional genomics approach. Yeast 17:302–306CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Heasman J (2002) Morpholino oligos: making sense of antisense? Dev Biol 243:209–214CrossRefPubMedGoogle Scholar
  3. 3.
    SPECIAL ISSUE (2001) Morpholino gene knockdowns – all 27 research reports in the July issue of the journal Genesis 30:89–200Google Scholar
  4. 4.
    Summerton J (1979) Intracellular inactivation of specific nucleotide sequences: a general approach to the treatment of viral diseases and viral-mediated cancers. J Theor Biol 78:77–99CrossRefPubMedGoogle Scholar
  5. 5.
    Summerton J (1979) Sequence-specific crosslinking agents for nucleic acids: design and functional group testing. J Theor Biol 78:61–75CrossRefPubMedGoogle Scholar
  6. 6.
    Summerton J, Hoenig S, Butler C, Chvapil M (1977) The mechanism of hemolysis by silica and its bearing on silicosis. Exp Mol Pathol 26:113–128CrossRefPubMedGoogle Scholar
  7. 7.
    Summerton J, Bartlett P (1978) Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA. J Mol Biol 122:145–162CrossRefPubMedGoogle Scholar
  8. 8.
    Stephenson M, Zamecnik P (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75:285–288CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zamecnik P, Stephenson M (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Miller PS, Yano J, Yano E, Carroll C, Jayaraman K, Ts’o POP (1979) Nonionic nucleic acid analogues. Synthesis and characterization of didexoyribonucleoside methylphosphonates. Biochemistry 18:5134–5143CrossRefPubMedGoogle Scholar
  11. 11.
    Miller PS, Agris CH, Blake KR, Murakami A, Spitz SA, Reddy MP, Ts’o POP (1983) Nonionic oligonucleoside analogs as new tools for studies on the structure and function of nucleic acids inside living cells. In: Pullman B, Jortner J (eds) Nucleic acids: the vectors of life. D. Reidel Publishing, Dordrecht, p 521CrossRefGoogle Scholar
  12. 12.
    Blake KR, Murakami A, Spitz SA, Glave SA, Reddy MP, Ts’o POP, Miller PS (1985) Hybridization arrest of globin synthesis in rabbit reticulocyte cells by oligodeoxyribonucleoside methylphosphonates. Biochemistry 24:6139–6145CrossRefPubMedGoogle Scholar
  13. 13.
    Miller P, Barrett J, Ts’o P (1974) Synthesis of oligodeoxyribonucleotide ethylphosphotriesters and their specific complex formation with transfer ribonucleic acid. Biochemistry 13:4887–4986CrossRefPubMedGoogle Scholar
  14. 14.
    Stirchak E, Summerton J, Weller D (1987) Uncharged stereoregular nucleic acid analogues. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages. J Org Chem 52:4202–4206CrossRefGoogle Scholar
  15. 15.
    Stirchak E, Summerton J, Weller D (1989) Uncharged stereoregular nucleic acid analogues. 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 17:6129–6141CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Summerton J., and Weller D. (1993) Uncharged Morpholino-based polymers having phosphorous containing chiral inter-subunit linkages. US Patent 5,185,444.Google Scholar
  17. 17.
    Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–195CrossRefPubMedGoogle Scholar
  18. 18.
    Summerton J, Stein D, Huang S, Matthews P, Weller D, Partridge M (1997) Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7:63–70CrossRefPubMedGoogle Scholar
  19. 19.
    Summerton J (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489:141–158CrossRefPubMedGoogle Scholar
  20. 20.
    Summerton J (2006) Chapter 6: Morpholinos and PNAs compared. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 89–113CrossRefGoogle Scholar
  21. 21.
    Summerton J (2007) Morpholinos, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 7:651–660CrossRefPubMedGoogle Scholar
  22. 22.
    Wilczynska A, Bushell M (2015) The complexity of miRNA-mediated repression. Cell Death Differ 22:22–33CrossRefPubMedGoogle Scholar
  23. 23.
    Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A 84:7706–7710CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC (1988) Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A 85:7079–7083CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365:566–568CrossRefPubMedGoogle Scholar
  26. 26.
    Nielsen P, Egholm M (1999) Peptide nucleic acids protocols and applications. Horizon Scientific Press, NorfolkGoogle Scholar
  27. 27.
    Nielsen P (2006) Chapter 1: the many faces of PNA. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 3–17CrossRefGoogle Scholar
  28. 28.
    Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498CrossRefPubMedGoogle Scholar
  29. 29.
    Scherer L, Rossi J (2006) Chapter 8: recent applications of RNA interference (RNAi) in mammalian systems. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 133–147CrossRefGoogle Scholar
  30. 30.
    Gruber J, Manninga H, Tuschl T, Osborn M, Weber K (2005) Specific RNAi mediated gene knockdown in zebrafish cell lines. RNA Biol 2:101–105CrossRefPubMedGoogle Scholar
  31. 31.
    Summerton J (2016) Custom cocktail for curing any cancer: a strategy for destroying any cancer without harming the patient. J Drug Discov Dev Deliv 3(1): id 1020Google Scholar
  32. 32.
    Summerton J (2003) Custom cancer therapies: safe and effective treatments for most or all cancers. Ann NY Acad Sci 1002:189–196Google Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Gene Tools, LLCPhilomathUSA

Personalised recommendations